All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

June 13th 2025

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

June 13th 2025

ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia

June 13th 2025

ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.

Olutasidenib Maintenance Generates Durable RFS in IDH1-Mutated AML Following Induction CR/CRi

June 13th 2025

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction

June 13th 2025

A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria

June 13th 2025

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention

June 13th 2025

Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

June 13th 2025

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

FDA Grants Fast Track Designation to Nuvisertib for Myelofibrosis

June 13th 2025

The FDA granted fast track designation to nuvisertib for intermediate- or high-risk myelofibrosis.

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

June 13th 2025

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC

June 12th 2025

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo

June 12th 2025

Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML

June 12th 2025

Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.

Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD

June 12th 2025

Naval Daver, MD, discusses the evolving role of menin inhibition in acute myeloid leukemia and emerging data with revumenib.

Telisotuzumab Vedotin Elicits Responses in c-MET–Overexpressing NSCLC, Regardless of Prior Therapy

June 12th 2025

Telisotuzumab vedotin showed durable responses in c-MET–overexpressing, nonsquamous, EGFR-wildtype NSCLC, regardless of prior platinum or ICI therapy.

Researchers Identify Novel Target for High-Risk Multiple Myeloma

June 12th 2025

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.

FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.